Products Categories
| CAS No.: | 1306-06-5 |
|---|---|
| Name: | Hydroxyapatite |
| Molecular Structure: | |
|
|
| Formula: | Ca5.(OH).(PO4)3 |
| Molecular Weight: | 502.31 |
| Synonyms: | Tricalcium Phosphate (TCP);Mono Calcium Phosphate(MCP);Hy-Apatite;Tri-Tab;Hyaluronic acid(HA);Apaceram;Interpore 500;Interpore 200;Supertite 10;HAP-B;Monite; |
| EINECS: | 215-145-7 |
| Density: | 3.076 g/cm3(Temp: 18 °C) |
| Melting Point: | 1100 °C(lit.) |
| Boiling Point: | 158oC at 760 mmHg |
| Solubility: | water: 0.3 mg/mL |
| Appearance: | white powder |
| Hazard Symbols: |
 Xi
|
| Risk Codes: | 36/37/38 |
| Safety: | 26-36 |
| PSA: | 119.12000 |
| LogP: | 0.20920 |
- 144851-82-1METHYL2-AMINO-3-FLUOROBENZOATE
- 483366-12-7(2S,4R)-1-Boc-2-cyano-4-hydroxypyrrolidine
- 173606-50-3BOC-10-AMINODECANOIC ACID
- 361456-36-2METHYL (R)-(+)-ISOCYANATO-3-PHENYLPROPI&
- 5156-58-1N-(1-Benzyl-4-pipperidinyl)-N-phenylpropanamide HCl
- 81281-59-67-Benzylideneaminotheophylline
- 50288-62-5threo-Phenyl-2-piperidyl acetamide
- 82993-81-5D-threo-Ritalinic acid hydrochloride
- 47087-37-6Z-D-Glu-OMe
- 73441-42-6METHYL-5-CHLORO-2,2-DIMETHYLVALERATE
- 68131-39-5Alcohols,C12-15, ethoxylated
- 107-02-8Acrolein
- 70895-01-1Cyclohexanol, 4-(4-bromophenyl)-4-(dimethylamino)-1-(2-phenylethyl)-, hydrochloride, trans- (9CI)
- 144060-53-7Febuxostat
- 33069-62-4Paclitaxel
- 120511-73-11,3-Benzenediacetonitrile, α1,α1,α3,α3-tetramethyl-5-(1H-1,2,4-triazol-1-ylmethyl)-
- 220127-57-1Imatinib mesylate
- 114977-28-5Docetaxel
- 104987-11-3Tacrolimus
- 141-53-7Sodium formate
- 8001-54-5Quaternary ammonium compounds, alkylbenzyldimethyl, chlorides
- 9003-39-8Povidone
- 10161-34-9Trenbolone acetate
- 402957-28-2Telaprevir
- 68-19-9Cyanocobalamin
What can I do for you?
Get Best Price
Consensus Reports
Specification
The IUPAC name of Hydroxyapatite is pentacalcium hydroxide triphosphate. With the CAS registry number 1306-06-5, it is also named as Durapatite. The product's category is Inorganics , and the other registry numbers are 1059174-00-3; 12440-80-1; 136841-77-5; 196875-13-5. Besides, it is white powder, which should be stored in a cool, ventilated, dry place at -20 °C. In addition, its molecular formula is Ca5.(OH).(PO4)3 and molecular weight is 502.31.It is the mineral component of bones and teeth; it has been used therapeutically as a prosthetic aid and in the prevention and treatment of osteoporosis.
The other characteristics of Hydroxyapatite can be summarized as: (1)H-Bond Donor: 1; (2)H-Bond Acceptor: 13; (3)Rotatable Bond Count: 0; (4)Exact Mass: 501.675956; (5)MonoIsotopic Mass: 501.675956; (6)Topological Polar Surface Area: 260; (7)Heavy Atom Count: 21; (8)Complexity: 36.8; (9)EINECS: 215-145-7; (10)Melting Point: 1100 °C; (11)Solubility: H2O: 0.3 mg/mL.
Preparation of Hydroxyapatite: First, please wash and defecate the fresh bone. And then steam it to remove osseocolla and fat. At last, you would obtain this chemical by drying and crushing.
Uses of Hydroxyapatite: Hydroxyapatite is used to replace amputated bone as a filler or to promote bone ingrowth into prosthetic implants as a coating. And it is a calcium supplement derived from bovine bone to encourage natural growth of skin around it. Moreover, it can be analysed in order to reconstruct ancient diets in archaeology.
When you are using Hydroxyapatite , please be cautious about it as the following: it is irritating to eyes, respiratory system and skin. In case of contact with eyes, please rinse immediately with plenty of water and seek medical advice. And you should wear suitable protective clothing.
You can still convert the following datas into molecular structure:
(1)SMILES: [OH-].[O-]P(=O)([O-])[O-].[O-]P(=O)([O-])[O-].[O-]P(=O)([O-])[O-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2]
(2)InChI: InChI=1/5Ca.3H3O4P.H2O/c;;;;;3*1-5(2,3)4;/h;;;;;3*(H3,1,2,3,4);1H2/q5*+2;;;;/p-10
(3)InChIKey: XYJRXVWERLGGKC-RDRJDVFWAH
The toxicity data of Hydroxyapatite is as follows:
| Organism | Test Type | Route | Reported Dose (Normalized Dose) | Effect | Source |
|---|---|---|---|---|---|
| dog | LD50 | oral | > 30gm/kg (30000mg/kg) | Drugs in Japan Vol. -, Pg. 1007, 1995. | |
| mouse | LD50 | oral | > 99500mg/kg (99500mg/kg) | Drugs in Japan Vol. -, Pg. 1007, 1995. | |
| mouse | LD50 | subcutaneous | > 25500mg/kg (25500mg/kg) | Drugs in Japan Vol. -, Pg. 1007, 1995. | |
| rat | LD50 | oral | > 25350mg/kg (25350mg/kg) | Drugs in Japan Vol. -, Pg. 1007, 1995. | |
| rat | LD50 | subcutaneous | > 19850mg/kg (19850mg/kg) | Drugs in Japan Vol. -, Pg. 1007, 1995. |